Medline (MDLN) Q2 FY26 earnings call

Medline delivered robust top-line growth in Q2 FY26, driven by strong organic performance and new customer acquisitions, leading to a second upward revision of its full-year sales outlook. However, the company faces significant margin pressures from the Tracy fire, increased operational and quality investments, and retail channel softness, resulting in a lowered adjusted EBITDA guidance. Management emphasizes strategic investments for long-term growth and competitive positioning, while actively pursuing cost savings and evaluating future pricing actions to restore margin profiles.